Search

everythinglearnresearchcommunity

for

Search:↓

Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.

imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

Diphencyprone (DPC) is an effective and safe long-term treatment for alopecia areata, especially with maintenance therapy.

Diphenylcyclopropenone treatment helps prevent hair loss relapse in alopecia areata patients.

Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.

Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.

PUVA treatment led to significant hair regrowth in over half of the patients with alopecia areata totalis and universalis.

Most patients experienced hirsutism again after stopping hormone treatment, indicating long-term treatment is needed to maintain results.

Autoimmune diseases with high tissue recovery often relapse and remit, while those with low recovery rarely remit.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Bimatoprost was found to be safer and more effective than mometasone furoate for treating scalp hair loss.

Cryotherapy may help hair regrowth in alopecia areata with possibly lower relapse rates than steroids.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

People who get alopecia areata after age 50 usually have mild symptoms, high chances of hair regrowth, and often have other health conditions.

Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

Intralesional triamcinolone acetonide is more effective but has a higher relapse rate than platelet-rich plasma for treating alopecia areata.

Alopecia areata has a high chance of persisting and relapsing, with a significant risk of total hair loss, especially if it starts in childhood.

Treatments for acute leukaemia lead to high remission rates, but relapses occur, requiring ongoing advancements in care.

The health of the sentinel lymph node is the best indicator of survival for patients with thick skin cancer.

Pulse steroid therapy for alopecia areata shows a 43% complete response rate but has a high relapse rate, especially in children.

Alopecia areata is a reversible, autoimmune-related hair loss that can have significant emotional impact and uncertain treatment effectiveness.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.

Herbal lotions are effective for severe hair loss, with a 64.8% success rate, but relapse is common and long-term management requires allergen control and possible corticosteroid use.

Platelet-rich plasma (PRP) is effective in treating various skin conditions and improving hair density, thickness, and patient satisfaction, with lower relapse rates for Alopecia Areata.